Journal
CLINICAL PHARMACOLOGY & THERAPEUTICS
Volume 100, Issue 3, Pages 220-222Publisher
WILEY
DOI: 10.1002/cpt.360
Keywords
-
Categories
Ask authors/readers for more resources
The use of programmed cell death 1 ligand 1 (PD-L1) as a predictive biomarker to select patients to receive programmed cell death 1 (PD-1) or PD-L1 inhibitors in non-small cell lung cancer (NSCLC) is limited by the definitions of positivity, interassay agreement, and intra- and intertumoral heterogeneity of expression. Although PD-L1 expression enriches for responses, the lack of expression does not exclude clinical benefit.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available